Grading System Strength of Recommendation
Grade 1 = stronga
Grade 2 = weakerb a
A = high
Quality of Evidence B = moderate C = low
Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. b Grade 2 suggests that individual patient values may lead to different choices.
Abbreviations ACCP, American College of Chest Physicians; ACT, activated clotting time; aPTT, activated partial thromboplastin time; DIC, disseminated intravascular coagulation; DVT, deep vein thrombosis; ECT, ecarin clotting time; ELISA, enzyme-linked immunosorbent assay; FDA, US Food and Drug Administration; HIPA, heparin-induced platelet activation; HIT, heparin- induced thrombocytopenia; HITT, heparin-induced thrombocytopenia with thrombosis; INR, international normalization ratio; IV, intravenous; LMWH, low-molecular-weight hepa- rin; MI, myocardial infarction; PCI, percutaneous coronary intervention; PF4, platelet factor 4; subcut, subcutaneous; SRA, serotonin release assay; UFH, unfractionated heparin; VKA, vitamin K antagonist
Source Linkins L-A, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther MA. Treat- ment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Pre- vention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical
Practice Guidelines. Chest. 2012;141(2 Suppl):e495S-e530S. doi:10.1378/chest. 11-2303.
Disclaimer
This Guideline attempts to define principles of practice that should produce high-quality patient care. It focuses on the needs of primary care practice, but also is applicable to providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aſter consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool.
HIT021209
5740 Executive Drive Suite 218 Baltimore, MD 21228 TEL: 410-869-3332 • FAX: 410-744-2150 For additional copies: orders@GuidelineCentral.com Copyright © 2012 All rights reserved
